File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.clinthera.2017.05.119
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Clinical study of plasma lipocalin-2 and endothelial function
Title | Clinical study of plasma lipocalin-2 and endothelial function |
---|---|
Authors | |
Issue Date | 2017 |
Publisher | Excerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/clinthera |
Citation | The 13th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Prague, Czech Republic, 24-27 June 2017. Clinical Therapeutics, 2017, v. 39 n. 8S, p. e38 How to Cite? |
Abstract | Background
Recent animal studies suggested that lipocalin-2 plays a key role in the development of hypertension, atherosclerosis and endothelial dysfunction. Lipocalin-2 knockout mice are resistant to the harmful effects of high fat diet and do not develop hypertension or atherosclerosis. We therefore hypothesised that lipocalin-2 is also related to endothelial function in man.
Methods
We measured plasma lipocalin-2 concentration and brachial artery flow-mediated dilatation (FMD) in 245 subjects (201 men, 44 women; mean age±SD, 68±9 y), of whom 151 had hypertension, 80 had diabetes mellitus and 240 were on lipid lowering therapy. Lipocalin-2 was measured using a highly-specific ELISA, with intra- and interassay coefficients of variation of 3.8-6.0% and 3.1–5.2% respectively. Brachial artery diameter and flow velocity were measured using a 7.5MHz ultrasound probe. Scans were taken at baseline, 5 minutes after tourniquet inflation and after sublingual glyceryl trinitrate spray. The percentage change in brachial artery diameter following reactive hyperaemia was calculated. The coefficient of variation of FMD determination was 5%.
Results
The median (IQR) plasma lipocalin-2 concentration was 50 (29-75) ng/mL. There was no sex difference. Plasma lipocalin-2 level correlated with serum creatinine (ρ=0.23, p<0.001) but not FMD (ρ=0.005, p=0.94). Instead, FMD decreased with age (ρ=-0.14, p=0.03). It is also lower in individuals with diabetes (p=0.044).
Conclusions
Endothelial function decreases with age and diabetes, but is unrelated to plasma lipocalin-2 level. This suggests that plasma lipocalin-2 level is not a major determinant of endothelial function. However, plasma lipocalin-2 is a marker for renal dysfunction. |
Persistent Identifier | http://hdl.handle.net/10722/247879 |
ISSN | 2023 Impact Factor: 3.2 2023 SCImago Journal Rankings: 0.875 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cheung, BMY | - |
dc.contributor.author | Wang, Y | - |
dc.contributor.author | Lam, KSL | - |
dc.contributor.author | Tse, HF | - |
dc.date.accessioned | 2017-10-18T08:34:08Z | - |
dc.date.available | 2017-10-18T08:34:08Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | The 13th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Prague, Czech Republic, 24-27 June 2017. Clinical Therapeutics, 2017, v. 39 n. 8S, p. e38 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | http://hdl.handle.net/10722/247879 | - |
dc.description.abstract | Background Recent animal studies suggested that lipocalin-2 plays a key role in the development of hypertension, atherosclerosis and endothelial dysfunction. Lipocalin-2 knockout mice are resistant to the harmful effects of high fat diet and do not develop hypertension or atherosclerosis. We therefore hypothesised that lipocalin-2 is also related to endothelial function in man. Methods We measured plasma lipocalin-2 concentration and brachial artery flow-mediated dilatation (FMD) in 245 subjects (201 men, 44 women; mean age±SD, 68±9 y), of whom 151 had hypertension, 80 had diabetes mellitus and 240 were on lipid lowering therapy. Lipocalin-2 was measured using a highly-specific ELISA, with intra- and interassay coefficients of variation of 3.8-6.0% and 3.1–5.2% respectively. Brachial artery diameter and flow velocity were measured using a 7.5MHz ultrasound probe. Scans were taken at baseline, 5 minutes after tourniquet inflation and after sublingual glyceryl trinitrate spray. The percentage change in brachial artery diameter following reactive hyperaemia was calculated. The coefficient of variation of FMD determination was 5%. Results The median (IQR) plasma lipocalin-2 concentration was 50 (29-75) ng/mL. There was no sex difference. Plasma lipocalin-2 level correlated with serum creatinine (ρ=0.23, p<0.001) but not FMD (ρ=0.005, p=0.94). Instead, FMD decreased with age (ρ=-0.14, p=0.03). It is also lower in individuals with diabetes (p=0.044). Conclusions Endothelial function decreases with age and diabetes, but is unrelated to plasma lipocalin-2 level. This suggests that plasma lipocalin-2 level is not a major determinant of endothelial function. However, plasma lipocalin-2 is a marker for renal dysfunction. | - |
dc.language | eng | - |
dc.publisher | Excerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/clinthera | - |
dc.relation.ispartof | Clinical Therapeutics | - |
dc.rights | Posting accepted manuscript (postprint): © <year>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.title | Clinical study of plasma lipocalin-2 and endothelial function | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Cheung, BMY: mycheung@hkucc.hku.hk | - |
dc.identifier.email | Lam, KSL: ksllam@hku.hk | - |
dc.identifier.email | Tse, HF: hftse@hkucc.hku.hk | - |
dc.identifier.authority | Cheung, BMY=rp01321 | - |
dc.identifier.authority | Lam, KSL=rp00343 | - |
dc.identifier.authority | Tse, HF=rp00428 | - |
dc.identifier.doi | 10.1016/j.clinthera.2017.05.119 | - |
dc.identifier.hkuros | 282093 | - |
dc.identifier.volume | 39 | - |
dc.identifier.issue | 8S | - |
dc.identifier.spage | e38 | - |
dc.identifier.epage | e38 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0149-2918 | - |